Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.3 0.24

Overview

Share price change

24h

Current

Min

12.3

Max

12.39

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

121.8

57.366

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+21.16% upside

Market Stats

By TradingEconomics

Market Cap

205M

2.1B

Previous open

12.06

Previous close

12.3

News Sentiment

By Acuity

100%

0%

325 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 sie 2026, 00:02 UTC

News
Correlated Moves

Delta Air Lines shares are higher in after-market trading following the court's approval of its joint venture with Grupo Aeroméxico and record Q2 revenue of $17.7 billion.

29 sie 2026, 00:02 UTC

News

Pinterest Inc shares declined in after-market trading following CFO Julia Brau Donnelly's resignation, effective October 30. Vikram Naidu will serve as interim CFO.

29 sie 2026, 00:02 UTC

News

Chevron is nearing multi-billion-dollar deals to expand operations in Venezuela, boosting shares in after-market trading amid rising global crude prices.

29 sie 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

29 sie 2026, 00:01 UTC

News

Planet Fitness shares are lower in after-market hours following a class action lawsuit alleging misleading statements about customer metrics and growth guidance.

29 sie 2026, 00:01 UTC

News

Blue Owl Capital Inc. shares rose in after-market trading following its $2.4 billion debt deal for Iren Ltd. to acquire Nvidia Blackwell Ultra GPUs.

29 sie 2026, 00:01 UTC

News

Vistra Corp reports gross revenue of $17.74 billion and net income of $944 million. Shares are higher in after-market hours, reflecting strong institutional confidence.

29 sie 2026, 00:01 UTC

News

Group 1 Automotive shares declined in after-market hours following multiple broker downgrades and price target reductions, including Barclays lowering its target to $365.

28 sie 2026, 23:56 UTC

News

nVent Electric PLC will acquire Maverick Power for $1.75 billion, with additional performance-based payments. Shares are higher during after-market hours following the announcement.

28 sie 2026, 23:46 UTC

News

Diamondback Energy shares declined after-market, despite earlier gains, amid rising market expectations for a rate hike and increased Treasury yields.

28 sie 2026, 23:46 UTC

News

Target Corp filed for a mixed securities shelf and registered 15.5 million shares under its employee incentive plan. Shares remained roughly flat in after-market hours.

28 sie 2026, 23:41 UTC

News

Blue Owl Capital gained in after-market trading after leading a $2.4 billion financing deal for Iren Ltd. to purchase Nvidia Blackwell Ultra GPUs.

28 sie 2026, 23:41 UTC

News

Group 1 Automotive Inc shares declined in after-market hours, pressured by ratings downgrades from Barclays PLC and Weiss Ratings amid rising Treasury yields.

28 sie 2026, 23:21 UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

28 sie 2026, 23:21 UTC

News

Intuit Inc. shares are trading lower in after-market hours following a class action lawsuit alleging misleading statements about its financial performance and competitive advantages.

28 sie 2026, 23:06 UTC

News

Coherus Oncology's $50 million common share offering pressures shares lower in after-market trading, marking a pullback from recent highs.

28 sie 2026, 23:06 UTC

News

BioNTech SE shares are higher in after-market trading, supported by a Strong Buy rating and a cash position of $19.28 billion for R&D efforts.

28 sie 2026, 23:06 UTC

Macro Event
News

Bitcoin is trading lower as hawkish comments from Federal Reserve Chairman Kevin Warsh raise interest rate expectations and geopolitical tensions impact investor confidence.

28 sie 2026, 23:06 UTC

Macro Event
News

Bitcoin is trading lower as hawkish comments from Federal Reserve Chairman Kevin Warsh raise interest rate hike expectations and geopolitical tensions impact market confidence.

28 sie 2026, 23:06 UTC

News

Lowe's Companies declared a quarterly cash dividend of $1.25 per share, boosting shares in after-market trading following the announcement.

28 sie 2026, 23:06 UTC

News

Visa Inc shares are higher in after-market trading following a partnership with Dunamu to develop stablecoin payments and cross-border remittance services.

28 sie 2026, 23:06 UTC

News

Michael Burry has reduced his stake in PayPal as acquisition talks with Advent International and Stripe have ended. Shares are slightly higher in after-hours trading.

28 sie 2026, 23:02 UTC

News

Halliburton Co is positioned for multi-billion-dollar deals in Venezuelan crude reserves, contributing to higher shares in after-market hours.

28 sie 2026, 23:01 UTC

News

Pinterest Inc shares declined in after-market trading following the resignation announcement of CFO Julia Brau Donnelly, effective October 30, 2026. Trading remains weak overall.

28 sie 2026, 23:01 UTC

News

Chemours Co faces an investigation by Pomerantz LLP over potential securities law violations. Shares are trading higher in after-market hours despite concerns over internal controls.

28 sie 2026, 23:01 UTC

News

Alnylam Pharmaceuticals shares rose in after-market hours, despite concerns from a failed cardiomyopathy trial. The company's market capitalization stands at $31.57 billion.

28 sie 2026, 23:01 UTC

News

Flowers Foods shares are lower in after-market trading following the filing of a mixed securities shelf, raising potential concerns about dilution and financial strategy.

28 sie 2026, 23:01 UTC

Event
News

Eli Lilly's shares rise in after-market trading following FDA approval of Mounjaro for reducing cardiovascular risks in type 2 diabetes patients.

28 sie 2026, 23:01 UTC

News

Chevron is nearing multi-billion-dollar deals to expand operations in Venezuela, targeting two heavy-oil fields. Shares are trading higher in after-market hours.

28 sie 2026, 23:01 UTC

News

McKesson Corp disclosed a cybersecurity incident affecting its information systems, with shares trading lower in after-market hours amid broader market weakness.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

21.16% upside

12 Months Forecast

Average 15 USD  21.16%

High 16 USD

Low 14 USD

Based on 2 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat